The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Changes in nutritional status associated with unresectable pancreatic cancer
Open accessAbstract
Weight loss is common in patients with pancreatic cancer; however, the nature and progress of their nutritional depletion are not well documented. In this study, pre-illness weight and duration of weight loss were recorded in 20 patients with histologically confirmed unresectable cancer of the pancreas. Patients then underwent nutritional analysis at monthly intervals until death. The median period of assessment was 27 weeks (interquartile range 22.5-38.0 weeks). At the time of diagnosis, all patients had lost weight [median 14.2% (10.0-20.0%) of pre-illness stable weight], and this weight loss was progressive, increasing to a median of 24.5% by the time of the last assessment (P =0.0004). Body mass index was significantly reduced from a pre-illness median value of 24.9 kg m-2 (22.4-27.4 kg m-2) to 20.7 kg m-2 (19.5-23.6 kg m-2) at the time of diagnosis and further to 17.7 kg m-2 (16.6-23.1 kg m-2) just before death (P =0.0003). Further evidence of tissue depletion was evident from the significant reductions in lean body mass [43.4 kg (36.9-53.0 kg) to 40.1 kg (33.5-50.7 kg) P =0.008] and fat mass [12.5 kg (8.9-17.8 kg) to 9.6 kg (6.3-15.1 kg) P =0.03). This study confirms that the majority of patients with unresectable pancreatic cancer have already undergone significant weight loss by the time of diagnosis and that the natural history of this process is one of inexorable progression. These results highlight the need for selective non-toxic therapeutic intervention to attenuate cachexia and indicate that such interventions should be instituted early in the course of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Body composition in chronic undernutrition
Barac-Nieto, M., Spurr, G., Lotero, H., & Maksud, M. (1978) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/31.1.23 · Cited by 162
Cited by
Tisdale, M. J. (2009) · Physiological Reviews · doi:10.1152/physrev.00016.2008 · Cited by 1,192
Bauer, J., Capra, S., & Ferguson, M. (2002) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601412 · Cited by 1,178
Tisdale, M. J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc927 · Cited by 982
ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology
Arends, J., Bodoky, G., Bozzetti, F., Fearon, K., Muscaritoli, M., Selga, G., van Bokhorst-de van der Schueren, M. A. E., von Meyenfeldt, M., Zürcher, G., Fietkau, R., et al. (2006) · Clinical Nutrition · doi:10.1016/j.clnu.2006.01.020 · Cited by 930
Self-citationFearon, K. C., Voss, A. C., & Hustead, D. S. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1345 · Cited by 779
Self-citationSarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer
Tan, B. H. L., Birdsell, L. A., Martin, L., Baracos, V. E., & Fearon, K. C. H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1525 · Cited by 653
Self-citationMayers, J. R., Wu, C., Clish, C. B., Kraft, P., Torrence, M. E., Fiske, B. P., Yuan, C., Bao, Y., Townsend, M. K., Tworoger, S. S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3686 · Cited by 649
Metabolomics in cancer research and emerging applications in clinical oncology
Schmidt, D. R., Patel, R., Kirsch, D. G., Lewis, C. A., Vander Heiden, M. G., & Locasale, J. W. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21670 · Cited by 648
Fearon, K. C. H. (2003) · Gut · doi:10.1136/gut.52.10.1479 · Cited by 603
Self-citationTisdale, M. J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.23.1763 · Cited by 487
ESPEN Guidelines on Parenteral Nutrition: Non-surgical oncology
Bozzetti, F., Arends, J., Lundholm, K., Micklewright, A., Zurcher, G., & Muscaritoli, M. (2009) · Clinical Nutrition · doi:10.1016/j.clnu.2009.04.011 · Cited by 485
Barber, M. D., Ross, J. A., Voss, A. C., Tisdale, M. J., & Fearon, K. C. H. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690654 · Cited by 459
Self-citationThalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial
Gordon, J. N., Trebble, T. M., Ellis, R. D., Duncan, H. D., Johns, T., & Goggin, P. M. (2005) · Gut · doi:10.1136/gut.2004.047563 · Cited by 322
Fearon, K. C. H., Barber, M. D., Moses, A. G., Ahmedzai, S. H., Taylor, G. S., Tisdale, M. J., & Murray, G. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5724 · Cited by 281
Self-citationEffect of Oral Eicosapentaenoic Acid on Weight Loss in Patients With Pancreatic Cancer
Wigmore, S. J., Barber, M. D., Ross, J. A., Tisdale, M. J., & Fearon, K. C. H. (2000) · Nutrition and Cancer · doi:10.1207/s15327914nc3602_6 · Cited by 275
Self-citationWhite, J. P., Baynes, J. W., Welle, S. L., Kostek, M. C., Matesic, L. E., Sato, S., & Carson, J. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024650 · Cited by 260
“Often cancer patients are not diagnosed until significant body weight loss has occurred [2], which limits treatment options in cachectic patients [3].”
Flegal, K. M., Graubard, B. I., Williamson, D. F., & Cooper, R. S. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwq341 · Cited by 223
Ozola Zalite, I., Zykus, R., Francisco Gonzalez, M., Saygili, F., Pukitis, A., Gaujoux, S., Charnley, R. M., & Lyadov, V. (2015) · Pancreatology · doi:10.1016/j.pan.2014.11.006 · Cited by 174
Molecular pathways: cachexia signaling-A targeted approach to cancer treatment
Miyamoto, Y., Hanna, D. L., Zhang, W., Baba, H., & Lenz, H.-J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0495 · Cited by 111
Metadata
- Authors
- Wigmore, S., Plester, C., Richardson, R., & Fearon, K.
- Venue
- British Journal of Cancer
- Published
- 1997-01
- Volume
- 75
- Issue
- 1
- Pages
- 106-109
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2060078508
- Cited by
- 247
- References
- 1
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.